National Cooperative Drug Discovery Groups for Cancer

The summary for the National Cooperative Drug Discovery Groups for Cancer grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

National Cooperative Drug Discovery Groups for Cancer: The Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI) invites applications to continue the National Cooperative Drug Discovery Group (NCDDG) Program for the discovery of new and more effective anticancer treatments. This program will further the NIH Roadmap Initiatives (http://nihroadmap.nih.gov) and the NCI goal of eliminating the suffering and death due to cancer by the year 2015. For this Request for Applications (RFA), the term NCDDG will apply, whether the products are from natural sources or of synthetic or biological origin. Applications are sought from both new and re-competing NCDDGs (also called Groups). This RFA will support broad, innovative, interdisciplinary, multi- project approaches to the discovery of new, rationally based or natural-source derived anticancer treatments or strategies. The initiative provides a framework for interactions that will reduce the time from concept to product. A multi-institutional, public-private partnership approach involving academic, nonprofit, and/or commercial/industrial institutions with Government staff participation is envisioned because the creative talents in the required scientific disciplines are rarely available in a single institution. Although not required, the active participation of industry is encouraged because it will allow this segment of the scientific community to contribute its considerable intellectual and material resources. Further, the interaction of academic and non-profit research institutions with industry and Government will facilitate subsequent development and marketing of new therapies, although these latter activities are not within the scope of this RFA. Biological or molecular targets for drug discovery and the sources and types of natural products to be investigated will be selected by the applying Group. Subsequent studies required for development of new treatments (e.g., formulation development, large-scale production for clinical trials, or toxicology in support of Investigational New Drug Applications, etc.) as well as the clinical trial itself, are beyond the scope of this RFA. However, a timely evaluation of products is encouraged. The development of analogs of established or well-studied anticancer agents is not responsive to this RFA.